An observational study for schizophrenia relapse prediction

Janssen Research and Development LLC0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•Participants and their legally acceptable representative where applicable must
•be able to sign an informed consent form (ICF) indicating that he or she
•understands the purpose of and procedures required for the study and is willing
•to participate for the duration of the study
•- Have a clinical diagnosis of schizophrenia made by a clinician with
•understanding of the criteria for schizophrenia or schizoaffective disorder, per
•the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5),
•and had at least 1 relapse, in the opinion of the investigator, within the last 12
•months prior to date of informed consent
•- Must be receiving an OAP treatment regimen at the time of enrollment
•- Must be able to speak, read, and understand English and/or the local Indian
•language as the patient reported outcome instruments will be validated in
•regional languages

•Has treatment resistant schizophrenia (that is, currently receiving clozapine or
•electroconvulsive therapy [ECT])
•- Is on long-acting injectable antipsychotic regimen at the time of screening
•- Has a moderate to severe substance use disorder (other than nicotine), as
•determined by the investigator
•- Has a significant risk of suicide or active suicidality with a plan as indicated by
•the Columbia-Suicide Severity Rating Scale (C-SSRS) assessment
•- Has an immediate need for hospitalization (that is, the participant is already in

发起方

Janssen Research and Development LLC